Ekso Bionics (NASDAQ:EKSO) Issues Earnings Results

Ekso Bionics (NASDAQ:EKSO) announced its earnings results on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Yahoo Finance reports. The firm had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. Ekso Bionics had a negative net margin of 79.48% and a negative return on equity of 95.36%. During the same period in the previous year, the firm earned ($0.31) EPS.

Ekso Bionics Stock Down 25.9 %

NASDAQ:EKSO traded down $0.39 during trading hours on Tuesday, hitting $1.10. The company’s stock had a trading volume of 335,148 shares, compared to its average volume of 130,427. The stock has a market capitalization of $19.99 million, a P/E ratio of -1.13 and a beta of 1.51. The stock has a fifty day moving average of $1.16 and a 200-day moving average of $1.47. The company has a current ratio of 2.81, a quick ratio of 2.11 and a debt-to-equity ratio of 0.33. Ekso Bionics has a 52-week low of $0.62 and a 52-week high of $3.13.

Analyst Ratings Changes

A number of brokerages have issued reports on EKSO. StockNews.com began coverage on Ekso Bionics in a research report on Tuesday. They issued a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Ekso Bionics in a research report on Tuesday. Finally, Lake Street Capital initiated coverage on Ekso Bionics in a research report on Monday, June 24th. They set a “buy” rating and a $2.50 price objective on the stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.